Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Bourgeon Capital Management LLC Takes Position in Akero Therapeutics, Inc. $AKRO
03:47am, Saturday, 03'rd Jan 2026
Bourgeon Capital Management LLC acquired a new position in shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) in the third quarter, according to its most recent Form 13F filing with the Securities and
Corient Private Wealth LLC Takes $3.93 Million Position in Akero Therapeutics, Inc. $AKRO
03:38am, Monday, 22'nd Dec 2025
Corient Private Wealth LLC acquired a new stake in shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) during the undefined quarter, according to the company in its most recent filing with the Securitie
Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO
03:59am, Saturday, 13'th Dec 2025
Alkeon Capital Management LLC increased its holdings in Akero Therapeutics, Inc. (NASDAQ: AKRO) by 19.3% during the second quarter, according to its most recent disclosure with the SEC. The institutio
Novo Nordisk has completed its acquisition of Akero Therapeutics
08:51am, Tuesday, 09'th Dec 2025
Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk's acquisition of Akero,
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
PHILADELPHIA , Nov. 12, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compe
PHILADELPHIA , Nov. 4, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of i
PHILADELPHIA , Oct. 29, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of it
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Recommendation of “Hold” from Analysts
01:32am, Wednesday, 22'nd Oct 2025
Shares of Akero Therapeutics, Inc. (NASDAQ: AKRO - Get Free Report) have earned an average recommendation of "Hold" from the thirteen ratings firms that are covering the firm, MarketBeat.com reports.
My Top 3 Pharma Stocks
11:38am, Monday, 20'th Oct 2025
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of A
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
05:30pm, Friday, 10'th Oct 2025
NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
Akero Therapeutics soars after Novo Nordisk set for $5.2B cash acquisition
01:30pm, Friday, 10'th Oct 2025
Novo Nordisk said on Thursday it would acquire Akero Therapeutics for up to $5.2 billion in cash, marking a significant push into treatments for fatty liver disease as the Danish drugmaker seeks to br
Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX
07:30am, Friday, 10'th Oct 2025
Akero Therapeutics is being acquired by Novo Nordisk for up to $5.2 billion, driven by strong phase 2b results for EFX in F2/F3 pre-cirrhotic and compensated cirrhosis F4 MASH patients. Akero's EFX sh
